Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705755 · ClinicalTrials.gov registry record · Phase 2
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
A Phase 2 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02705755 is a Phase 2 study that has completed, run by Theravance Biopharma. The registered enrollment target is 34 participants.
The verdict
NCT02705755, a Phase 2 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.
Interventions
- DRUG Placebo
- DRUG TD-9855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-09-09 |
| Est. Completion | 2018-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02705755
The ClinicalTrials.gov registry entry for NCT02705755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02705755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02705755 about?
NCT02705755 is a clinical study titled "TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)". This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms ...
What is the current status of trial NCT02705755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-09-09. Estimated completion is 2018-11-28.
What interventions are being tested in trial NCT02705755?
The interventions under investigation include: Placebo (DRUG), TD-9855 (DRUG).
Who is sponsoring clinical trial NCT02705755?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.